Standard Care With or Without Early Palliative Care Provided by Palliative Care Specialist in Advanced Non-small Cell Lung Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

104 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-04-02

Study Completion Date

2027-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Early palliative care has been shown to improve the survival of advanced lung cancer patients. However, most of the clinical studies were performed in the era when systemic treatment options for this disease were limited. Currently, many effective treatment options are available, including targeted therapy and immunotherapy. These novel agents improve the treatment outcomes while having less toxicity compared to conventional chemotherapy. Moreover, medical oncologists are now trained to provide palliative care for patients. This study was designed to demonstrate whether early palliative care provided by the palliative care specialist still improves the quality of life or survival of advanced lung cancer patients compared to standard care provided by the medical oncologist.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Standard of Care Lifestyle Support for Stage III NSCLC Patients

NCT05287971

Non Small Cell Lung Cancer

WITHDRAWN

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

NCT04613804

NSCLC Stage IV

UNKNOWN PHASE2

Standard Therapy Given With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer

NCT00003240

Lung Cancer

UNKNOWN PHASE3

Novel Palliative Care Model for Advanced Cancer Patients: A Randomized Controlled Trial Study

NCT04242251

Cancer

COMPLETED NA

A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT04222972

RET-fusion Non Small Cell Lung Cancer Lung Neoplasm Carcinoma, Non-Small-Cell Lung +14 more

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Advanced non-small cell lung cancer patients initiating a systemic treatment will be randomized to the early palliative care arm (attending a palliative care clinic once a month during the first three months concurrently with oncology clinic appointment) or the standard care arm (attending oncology clinic only). The patients will be asked to complete the quality of life questionnaires (FACT-L, EQ-5D-5L), mental health questionnaire (PHQ-9), and pain assessment once a month for three months and at the sixth month.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Lung Cancer - Non Small Cell Lung Cancer (NSCLC)

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Early palliative care with standard care

The patients will attend palliative care clinic once a month during the first three months together with oncology clinic visits

Group Type EXPERIMENTAL

Early palliative care integration

Intervention Type OTHER

The patients will attend palliative care clinic once a month during the first three months together with routine oncology clinic visits

Standard systemic treatment for advanced lung cancer

Intervention Type DRUG

Standard systemic treatment for advanced lung cancer

Standard care

The patients will attend oncology clinic as usual

Group Type ACTIVE_COMPARATOR

Standard systemic treatment for advanced lung cancer

Intervention Type DRUG

Standard systemic treatment for advanced lung cancer

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Early palliative care integration

The patients will attend palliative care clinic once a month during the first three months together with routine oncology clinic visits

Intervention Type OTHER

Standard systemic treatment for advanced lung cancer

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age at least 18 years old
* Pathologically confirmed advanced non-small cell lung cancer
* Plan to receive systemic treatment for lung cancer within three weeks
* ECOG performance status 0-2 with estimated life expectancy \> 24 weeks
* Having at least 4 scores according to Edmonton Symptom Assessment System (ESAS)
* Able to complete the questionnaires